Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Subscribe To Our Newsletter & Stay Updated
